Matches in Wikidata for { <http://www.wikidata.org/entity/Q65383168> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q65383168 description "clinical trial" @default.
- Q65383168 description "ensayu clínicu" @default.
- Q65383168 description "klinisch onderzoek" @default.
- Q65383168 description "клінічне випробування" @default.
- Q65383168 description "կլինիկական փորձարկում" @default.
- Q65383168 name "A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)" @default.
- Q65383168 name "A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen" @default.
- Q65383168 type Item @default.
- Q65383168 label "A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)" @default.
- Q65383168 label "A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen" @default.
- Q65383168 prefLabel "A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)" @default.
- Q65383168 prefLabel "A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen" @default.
- Q65383168 P1132 Q65383168-46571830-BD7C-4ED3-BBE4-53A053399F90 @default.
- Q65383168 P1476 Q65383168-FB5B30FE-A6C4-4305-9454-50A886C55CC7 @default.
- Q65383168 P17 Q65383168-06C4531F-8D29-4BC9-A29D-DBC4D010114E @default.
- Q65383168 P17 Q65383168-7A6AF54B-0D92-4EE0-86AD-4D735846C516 @default.
- Q65383168 P2899 Q65383168-C0F7D68D-F1BA-4DD3-AFF1-7722F07D9DCD @default.
- Q65383168 P3098 Q65383168-E5EA1258-8C05-4DF5-B8F6-0FDF70626570 @default.
- Q65383168 P31 Q65383168-1FF6B89C-633F-4FC3-AE59-524A3CCA322D @default.
- Q65383168 P580 Q65383168-E6F9561F-3E2A-4831-ADA1-F047CB0B5041 @default.
- Q65383168 P582 Q65383168-02537EDF-0A24-46D2-832A-A4B31796DBDA @default.
- Q65383168 P6099 Q65383168-32829D58-9FA5-4C37-B58F-85B3878ACD32 @default.
- Q65383168 P6099 Q65383168-FCDF2BBA-CE7A-4AE1-8BED-96254EE00551 @default.
- Q65383168 P8363 Q65383168-A74FF8BC-704F-4CC0-8717-3A8433BB888B @default.
- Q65383168 P859 Q65383168-92BCE7BF-296C-453F-A3F6-C5C1CEC51820 @default.
- Q65383168 P1132 "+134" @default.
- Q65383168 P1476 "An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease." @default.
- Q65383168 P17 Q142 @default.
- Q65383168 P17 Q183 @default.
- Q65383168 P2899 "+18" @default.
- Q65383168 P3098 "NCT00517530" @default.
- Q65383168 P31 Q30612 @default.
- Q65383168 P580 "2007-09-01T00:00:00Z" @default.
- Q65383168 P582 "2013-11-01T00:00:00Z" @default.
- Q65383168 P6099 Q42824440 @default.
- Q65383168 P6099 Q5452194 @default.
- Q65383168 P8363 Q78089383 @default.
- Q65383168 P859 Q212646 @default.